4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives

A new set of amino-3,5-dicyanopyridines was synthesized and biologically evaluated at the adenosine receptors (ARs). This chemical class is particularly versatile, as small structural modifications can influence not only affinity and selectivity, but also the pharmacological profile. Thus, in order to deepen the structure–activity relationships (SARs) of this series, different substituents were evaluated at the diverse positions on the dicyanopyridine scaffold. In general, the herein reported compounds show nanomolar binding affinity and interact better with both the human (h) A1 and A2A ARs than with the other subtypes. Docking studies at hAR structure were performed to rationalize the observed affinity data. Of interest are compounds 1 and 5, which can be considered as pan ligands as binding all the ARs with comparable nanomolar binding affinity (A1AR: 1, Ki = 9.63 nM; 5, Ki = 2.50 nM; A2AAR: 1, Ki = 21 nM; 5, Ki = 24 nM; A3AR: 1, Ki = 52 nM; 5, Ki = 25 nM; A2BAR: 1, EC50 = 1.4 nM; 5, EC50 = 1.12 nM). Moreover, these compounds showed a partial agonist profile at all the ARs. This combined AR partial agonist activity could lead us to hypothesize a potential effect in the repair process of damaged tissue that would be beneficial in both wound healing and remodeling.

[1]  R. Hay,et al.  Putting the burden of skin diseases on the global map , 2021, The British journal of dermatology.

[2]  M. Hardman,et al.  Wound healing: cellular mechanisms and pathological outcomes , 2020, Open Biology.

[3]  K. Varani,et al.  Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists , 2019, Pharmaceuticals.

[4]  S. Mishra,et al.  Retention of strong intramolecular hydrogen bonds in high polarity solvents in binaphthalene–benzamide derivatives: extensive NMR studies , 2019, RSC advances.

[5]  G. Marucci,et al.  Non-Nucleoside Agonists of the Adenosine Receptors: An Overview , 2019, Pharmaceuticals.

[6]  K. Varani,et al.  Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity. , 2019, Journal of medicinal chemistry.

[7]  E. D. du Toit,et al.  Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells , 2019, Purinergic Signalling.

[8]  W. Baumeister,et al.  Structure of the adenosine-bound human adenosine A1 receptor–Gi complex , 2018, Nature.

[9]  K. Varani,et al.  The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor. , 2018, European journal of medicinal chemistry.

[10]  Nicole Diedrichs,et al.  Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases , 2017, ChemMedChem.

[11]  K. Varani,et al.  Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis , 2017, International journal of molecular sciences.

[12]  G. Marucci,et al.  Simulation and Comparative Analysis of Different Binding Modes of Non‐nucleoside Agonists at the A2A Adenosine Receptor , 2016, Molecular informatics.

[13]  K. Varani,et al.  Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? , 2016, Trends in pharmacological sciences.

[14]  P. Maiti,et al.  First report of multiple metal ions containing glass–ceramic material as a heterogeneous ditopic catalyst for the chromatography free synthesis of 2-amino-3,5-dicarbonitrile-6-arylthio-pyridines in water , 2015 .

[15]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[16]  David Rodríguez,et al.  Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..

[17]  K. Varani,et al.  TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice , 2014, Neuropharmacology.

[18]  B. Cronstein,et al.  Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist , 2013, British journal of pharmacology.

[19]  C. Langmead,et al.  Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.

[20]  J Bajgar,et al.  Transdermal drug delivery in vitro using diffusion cells. , 2012, Current medicinal chemistry.

[21]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[22]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[23]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[24]  C. Kunick,et al.  Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. , 2010, European journal of medicinal chemistry.

[25]  K. Varani,et al.  Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. , 2009, Arthritis and rheumatism.

[26]  M. Sridhar,et al.  Novel ZnCl 2-catalyzed one-pot multicomponent synthesis of 2-amino-3,5-dicarbonitrile-6-thio-pyridines , 2009 .

[27]  B. Cronstein,et al.  Adenosine receptor agonists for promotion of dermal wound healing. , 2009, Biochemical pharmacology.

[28]  Hui Lu,et al.  A single-molecule perspective on the role of solvent hydrogen bonds in protein folding and chemical reactions. , 2008, Chemphyschem : a European journal of chemical physics and physical chemistry.

[29]  P. Pacher,et al.  A2A receptors in inflammation and injury: lessons learned from transgenic animals , 2008, Journal of leukocyte biology.

[30]  A. Kornienko,et al.  One-step synthesis of heterocyclic privileged medicinal scaffolds by a multicomponent reaction of malononitrile with aldehydes and thiols. , 2007, The Journal of organic chemistry.

[31]  F. Attaby,et al.  Synthesis, Reactions, and Antiviral Activity of 6′-Amino-2′-thioxo-1′,2′-dihydro-3,4′-bipyridine-3′,5′-dicarbonitrile , 2007 .

[32]  A. IJzerman,et al.  ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Kornienko,et al.  One-step, three-component synthesis of pyridines and 1,4-dihydropyridines with manifold medicinal utility. , 2006, Organic letters.

[34]  A. IJzerman,et al.  A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. , 2005, Journal of medicinal chemistry.

[35]  A. IJzerman,et al.  New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.

[36]  W. Bachovchin,et al.  Review: Contributions of NMR spectroscopy to the study of hydrogen bonds in serine protease active sites , 2001 .

[37]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[38]  R. Paes-de-Carvalho,et al.  Long-term activation of adenosine A2a receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons , 2001, Brain Research.

[39]  R. Cunha,et al.  Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.

[40]  J. Ribeiro,et al.  Fine-tuning neuromodulation by adenosine. , 2000, Trends in pharmacological sciences.

[41]  M Danhof,et al.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[42]  J. Dobson,et al.  Adenosine A2a receptors increase arterial endothelial cell nitric oxide. , 1998, The Journal of surgical research.

[43]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[44]  W. Buurman,et al.  Differential regulatory effects of adenosine on cytokine release by activated human monocytes. , 1994, Journal of immunology.

[45]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[46]  B. Cronstein,et al.  Adenosine receptors in wound healing, fibrosis and angiogenesis. , 2009, Handbook of experimental pharmacology.

[47]  Mark S. Gordon,et al.  Chapter 41 – Advances in electronic structure theory: GAMESS a decade later , 2005 .

[48]  Kwang S. Kim,et al.  Theory and applications of computational chemistry : the first forty years , 2005 .

[49]  A. de Mendonça,et al.  Adenosine and synaptic plasticity , 2001 .

[50]  K. Klotz,et al.  [3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. , 2000 .